To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Intra-Tumor DNA Methylati… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Contact form








 


Note! If you want an answer on a question you must specify your email address




Intra-Tumor DNA Methylation Heterogeneity in Glioblastoma; Implications for DNA Methylation-Based Classification.

Journal article
Authors Anna Wenger
Sandra Ferreyra Vega
Teresia Kling
Thomas Olsson
Asgeir Store Jakola
Helena Carén
Published in Neuro-oncology
Volume 21
Issue 5
Pages 616-27
ISSN 1523-5866
Publication year 2019
Published at Institute of Biomedicine, Department of Medical and Clinical Genetics
Institute of Neuroscience and Physiology, Department of Physiology
Sahlgrenska Cancer Center
Institute of Biomedicine, Department of Pathology
Institute of Neuroscience and Physiology, Department of Clinical Neuroscience
Pages 616-27
Language en
Links dx.doi.org/10.1093/neuonc/noz011
www.ncbi.nlm.nih.gov/entrez/query.f...
Subject categories Cancer and Oncology, Cell and Molecular Biology

Abstract

A feature of glioblastoma (GBM) is cellular and molecular heterogeneity, both within and between tumors. This variability causes a risk for sampling bias and potential tumor escape from future targeted therapy. Heterogeneous intra-tumor gene expression in GBM is well documented, but little is known regarding the epigenetic heterogeneity. Variability in DNA methylation within tumors would have implications for diagnostics, as methylation can be used for tumor classification, subtyping and determination of the clinically used biomarker MGMT promoter methylation. We therefore aimed to profile the intra-tumor DNA methylation heterogeneity in GBM and its effect on diagnostic properties.Three to four spatially separated biopsies per tumor were collected from 12 GBM patients. We performed genome-wide DNA methylation analysis and investigated intra-tumor variation.All samples were classified as GBM IDH wild type (wt)/mutated by methylation profiling, but the subclass differed within five tumors. Some GBM samples exhibited higher DNA methylation differences within tumors than between, and many CpG sites (mean: 17,000) had different methylation levels within the tumors. MGMT methylation status differed in IDH mutated patients (1/1).We demonstrated that intra-tumor DNA methylation heterogeneity is a feature of GBM. Although all biopsies were classified as GBM IDH wt/mutated by methylation analysis, the assigned subclass differed in samples from the same patient. The observed heterogeneity within tumors is important to consider for methylation-based biomarkers and future improvements in stratification of GBM patients.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?